Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
On Thursday, H.C. Wainwright maintained a Buy rating on Sangamo BioSciences (NASDAQ:SGMO) with a steadfast $10.00 price target, representing significant upside from the current price of $0.45. During the H.C. Wainwright 3rd Annual BioConnect Investor Conference held on May 20, Sangamo’s CEO Sandy Macrae expressed a strong belief in the company’s short-term strategy and forthcoming milestones. This has reinforced the firm’s confidence in the biopharmaceutical company’s prospects, despite the stock’s 80% decline over the past six months. According to InvestingPro data, analyst consensus remains moderately bullish, with price targets ranging from $1.50 to $10.00.
Sangamo is approaching significant events, including the critical Phase 2 data readout from the STAAR trial targeting Fabry disease, expected by the end of the second quarter of 2025. Analysts at H.C. Wainwright anticipate that a positive outcome from this trial could significantly reduce investment risk. This optimism is based on the potential for a Biologics License Application (BLA) submission in the first quarter of 2026, followed by a prospective approval of what could be the first gene therapy for this condition in the second half of 2026. InvestingPro analysis indicates the company’s financial health score is currently weak, with a cash burn rate that requires careful monitoring.
The company’s pipeline continues to advance with other treatments, such as ST-503 and ST-506, which are slated to enter clinical development in 2025 and 2026. Preliminary results from these programs are expected in the fourth quarter of 2026. Sangamo’s technological platforms, STAC-BBB and MINT, are also making headway. The STAC-BBB platform has already established three significant partnerships with industry leaders Genentech, Astellas, and Eli Lilly (NYSE:LLY).
Moreover, the MINT platform showcased new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, which took place from May 13 to May 17 in New Orleans. With discussions for additional partnerships ongoing and recent financial maneuvers extending Sangamo’s operational funding into the latter part of the third quarter of 2025, analysts see the company’s pipeline and platform execution as well-positioned to realize substantial growth from its current market position.
In other recent news, Sangamo Therapeutics reported its Q1 2025 earnings, highlighting a collaboration with Eli Lilly that could potentially bring in $1.4 billion in milestone payments. Despite this positive development, the company did not provide immediate financial results or guidance revisions, which seemed to affect investor sentiment. Sangamo announced significant cost reductions, extending its cash runway to late Q3 2025, and received an $18 million upfront license fee from Eli Lilly. Additionally, the company is preparing for a potential Biologics License Application (BLA) submission for its Fabry disease treatment in Q1 2026. Jefferies analysts recently revised their price target for Sangamo BioSciences, lowering it to $1.50 while maintaining a Buy rating. This adjustment followed Sangamo’s announcement of securing $23 million in financing, aimed at extending its financial runway. The company is actively seeking a commercialization partner for its Fabry disease program, with key data expected in June 2025. These developments are part of Sangamo’s strategic efforts to strengthen its position in the biotech industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.